Portfolio Lab

Argenx SE

  • Stock
  • Ticker ARGX
  • ISIN US04016X1019
  • Nasdaq
  • US listing in dollars (ADR)

Health care · Biotechnology · Netherlands

$925.70 −1.73%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Argenx SE since 05/2017, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ARGXGlobal equities (VT)

$10,000 grew to $30,656. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −38.2% in 12/2023, measured from the peak in 07/2023. It took 14 months to get back to the old peak.

1-year return
+0.8%
5-year return p.a.
+26.7%
Return p.a. since 05/2017
+47.5%
Volatility p.a.
49.3%
Largest decline
−38.2%

Financial statements

Amounts in $ millions from the company's annual financial reports, earnings per share in $ per ordinary share

Fiscal year202020212022202320242025
Income statement
Revenue41497–––4,151
Gross profit–––––3,701
Operating income-478-349-720-425-221,054
Net income-608-408-710-2958331,292
Earnings per share–––-5.1612.7819.57
Balance sheet
Total assets2,2792,8503,1344,5426,2038,683
Liabilities6053163214457041,360
Equity1,6742,5342,8144,0985,4987,323
Cash1,2171,3358012,0491,5003,491
Cash flow
Operating cash flow-398-607-863-420-83685
Capital expenditure-1.1-3.6-0.8-0.8-1.8-6.2
Free cash flow-400-610-864-421-85679

Annual returns

Best year 2020 at +83.2%, weakest 2023 at +0.4%. 8 of 8 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€54bn
Market cap in trading currency
$59.1bn
Enterprise value
$55.7bn
P/E
49.3
P/S
14.25
P/B
8.08
EV/Sales
13.41
EV/EBITDA
–
Earnings yield
2.0%
FCF yield
1.1%

Results (latest fiscal year)

Revenue
$4.15bn
Gross profit
$3.70bn
EBITDA
–
Net income
$1.29bn
Earnings per share
$19.57
Revenue growth
–
Earnings growth
+55.1%

Profitability

Gross margin
89.1%
Operating margin
25.4%
Net margin
31.1%
Return on equity
20.2%
Return on assets
14.9%

Balance sheet and cash flow

Cash
$3.49bn
Financial debt
–
Debt/equity %
–
Current ratio
5.23
Book value per share
$119.48
Operating cash flow
$685m
Free cash flow
$679m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
61.3m
Volume
236,017
Avg. volume 3 months
359,983
Relative volume
0.7

Price and technicals

Price
$925.70
1 day
−1.7%
52-week high
$1,058.90
52-week low
$663.93
Distance to 52-week high
−12.6%
Distance to 52-week low
+39.4%
Distance to 50-day line
+0.9%
Distance to 200-day line
+7.3%
RSI (14)
50
Volatility 1M
31.7%

Performance

1 week
−3.6%
1 month
+5.7%
3 months
−8.4%
6 months
+14.8%
YTD
+10.1%
1 year
+1.2%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has ARGX performed since 05/2017?

$10,000 grew to $402,478 by 20 Nov 2026, which is +47.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ARGX?

Volatility was 49.3% per year, measured on monthly returns. The largest decline from a peak was −38.2%, with the low in 12/2023.

How does ARGX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +10.6% per year at 15.5% volatility, ARGX returned +47.5% at 49.3%. The correlation of monthly returns was 0.24; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Argenx SE (ARGX): Return and risk | Portfolio Lab